Molecular Partners Demonstrates Reduction of Mortality and Potent Therapeutic Activity of Anti-COVID-19 DARPin® Candidates in Advanced COVID-19 Disease Model

Zurich-Schlieren, Switzerland, October 6, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced supportive preclinical data from in vivo assessments of its DARPin® candidates targeting SARS-CoV-2. These candidates show robust activity in an...

read more

Kuros Biosciences reports MagnetOs products approved in Australia

Schlieren (Zurich), Switzerland, October 5, 2020 – Kuros Biosciences BV, the Dutch subsidiary of Kuros Biosciences AG (SIX: KURN), today announced that MagnetOs Granules and MagnetOs Putty have both been entered on the Australian Register of Therapeutic Goods allowing marketing and sales on the Australian market.  Surgical Specialties Pty Ltd, Kuros’s...

read more